Relationship between Expression Level of β-tubulin-Ⅲ and Sensitivity of Chemotherapy in Patients with Stage Ⅱ Non-small Cell Lung Cancer
-
摘要: 目的 探讨Ⅱ期非小细胞肺癌(NSCLC)中Ⅲ型β微管蛋白（β-tubulin-Ⅲ）mRNA表达与诺维本+顺铂（NP）方案化疗敏感度的关系。 方法 单基因定量法检测已手术Ⅱ期NSCLC患者肿瘤组织中β-tubulin-ⅢmRNA表达，所有患者行NP方案化疗，并随访患者的无瘤生存时间（DFS）和总体生存率（OS），统计学分析β-tubulin-ⅢmRNA表达水平与患者DFS和OS的关系。 结果 73例患者的OS与β-tubulin-Ⅲ的表达有关(P<0.01)，患者的DFS与β-tubulin-Ⅲ的表达及淋巴结转移情况有关(P<0.01)。β-tubulin-Ⅲ低表达者的OS、DFS均高于β-tubulin-Ⅲ高表达者(P<0.05)。 结论 Ⅱ期NSCLC患者肿瘤组织中β-tubulin-Ⅲ表达水平可能是预测患者预后及化疗敏感度的一个指标，为选择合适化疗药物提供参考。
-
关键词:
- 肺肿瘤 /
- 化疗 /
- β-tubulin-Ⅲ
Abstract: Objective To explore the relationship between chemotherapy sensitivity and the expression level of β- tubulin-Ⅲ mRNA in patients with stage Ⅱ NSCLC. Methods The expression of β-tubulin-Ⅲ mRNA was measured by Quanti-Gene assay.All patients accepted NP chemotherapy, and disease-free survival time (DFS) and overall survival time (OS) was analyzed. Results The OS of patients was related with the expression level of β-tubulin-Ⅲ (P<0.01), the DFS was related with the expression level of β-tubulin-Ⅲ and lymph node metastasis (P<0.01).The OS and DFS in patients with lower-expression level of β- tubulin-Ⅲ were longer than those with over-expression (P<0.05). Conclusion The expression of β-tubulin-Ⅲ in patients with stage Ⅱ NSCLC might be a predictive factor for chemotherapy sensitivity and the prognosis,and a reference for agents choose.-
Key words:
- Lung cancer /
- Chemotherapy /
- β-tubulin-Ⅲ
-
-
[1] Seve P,Dumontet C.Class Ⅲ beta tubulin expression in nonsmall cell lung cancer[J].Rev Mal Respir,2010,27(4):383-6. [2] Eastham LL, Mills CN, Niles RM. PPARalpha/gamma expression and activity in mouseand human melanocytes and melanoma cells[J].Pharm Res,2008,25(6):1327-33. [3] Olaussen KA,DunantA,FouretP,et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy[J]. N Engl J Med, 2006,355(10):983-91. [4] Papadaki C,Sfakianaki M,Ioannidis G,et al.ERCC1 and BRAC1 mRNA expression levels in the primary tumor could predict the effectiveness of the second-line cisplatin-based chemotherapy in pretreated patients with metastatic non-small cell lung cancer[J].J Thorac Oncol,2012,7(4): 663-71. [5] Craig Reynolds,Coleman Obasaju,Michael J,et al.randomized phase Ⅲ trial of gemcitabine -based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non- small-cell lung cancer[J].J Clin Oncol,2009,27(34):5808-15. [6] Sève P,Reiman T,Dumontet C.The role of β Ⅲ tubulin in predicting chemoresistance in non- small cell lung cancer[J]．Lung Cancer,2010,67(2):136-43. [7] Koh Y,Jang B,Han SW,et al.Expression of class Ⅲ beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer[J].J Thorac Oncol,2010,5(3):320-5. [8] Sève P,Lai R,Reiman T,et al.Class Ⅲ beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small-cell lung cancer:analysis of NCIC JBR.10[J].Clin Cancer Res,2007,13(3):994-9. [9] Sève P,Isaac S,Trèdan O,et al.Expression of classⅢ{beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy[J].Clin Cancer Res, 2005, 11(15):5481-6. [10] Reiman T,Lai R,Veillard AS,et al.Cross-validation study of class Ⅲ beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer:analysis of four randomized trials[J].Ann Oncol,2012,23(1):86-93. [11] Stengel C,Newman SP,Leese MP,et al.Class Ⅲ beta-tubulin expression and in vitro resistance to microtubule targeting agents[J].Br J Cancer,2010,102(2):316-24.
计量
- 文章访问数: 1811
- HTML全文浏览量: 28
- PDF下载量: 315
下载:
